Loading...
Piperacillin 4mg+Tazobactam 0.5mg
A heavy-duty, broad-spectrum antibacterial injection designed for the intensive management of severe and complicated systemic infections. Stepip 4.5 combines Piperacillin, an extended-spectrum penicillin, with Tazobactam, a potent beta-lactamase inhibitor, to provide a frontline defense against multi-drug resistant pathogens.
A heavy-duty, broad-spectrum antibacterial injection designed for the intensive management of severe and complicated systemic infections. Stepip 4.5 combines Piperacillin, an extended-spectrum penicillin, with Tazobactam, a potent beta-lactamase inhibitor, to provide a frontline defense against multi-drug resistant pathogens.
Piperacillin 4gm works by inhibiting the synthesis of the bacterial cell wall. As an ureidopenicillin, it possesses a broad range of activity against both Gram-positive and Gram-negative aerobic and anaerobic bacteria, including the difficult-to-treat Pseudomonas aeruginosa.
Tazobactam 0.5gm acts as a highly effective "suicide inhibitor" of bacterial beta-lactamases. By binding to these defensive enzymes, it prevents the degradation of Piperacillin, allowing the antibiotic to remain lethal even to resistant bacterial strains.
The 8:1 ratio of Piperacillin to Tazobactam is scientifically optimized to broaden the antimicrobial spectrum. This combination is particularly effective against organisms that produce chromosomal and plasmid-mediated enzymes, which typically neutralize standard penicillins.
Stepip 4.5 is highly effective against a wide variety of anaerobic bacteria, making it a primary choice for treating complex mixed infections of the abdomen, pelvis, and soft tissues where multiple pathogens are present.
The formulation achieves high therapeutic concentrations in nearly all body compartments, including the lungs, skin, and intestinal mucosa. This rapid systemic distribution is essential for stabilizing patients in septic or critical conditions.
Due to its massive spectrum of activity, this injection is frequently used as an initial empiric treatment for serious hospital-acquired infections (nosocomial) while waiting for specific culture and sensitivity results.
Indication Hospital-Acquired Pneumonia (VAP), Complicated Intra-abdominal Infections, Severe Skin and Soft Tissue Infections (Diabetic Foot), Febrile Neutropenia, Complicated Urinary Tract Infections, Septicemia.
Product descriptions, dosage forms, and compositions listed on the website are for reference by licensed practitioners and distributors only.
